CLINICAL TRIAL: ESTROGEN PREVENTION TRIAL

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项由国家老龄研究所支持的随机、安慰剂对照、预防性临床试验，为期四年，有痴呆症家族史的65岁及以上女性接受Premarin/Prempro(基于子宫状况)与安慰剂对照，以努力防止阿尔茨海默病在易受家族病史影响的人群中发生。我们目前的试验招生对象为28名女性，目前仍在积极招生中。这项试验得到了玛丽·萨诺博士的RO-1的支持，她最近从哥伦比亚搬到了芒特山。纽约的西奈半岛。在竞争性更新现场访问期间，RO-1获得了159分，并相信资金将继续五年，以支持这项正在进行的工作。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, placebo-controlled, prevention-type clinical trial supported by the National Institute on Aging for a four-year period of exposure in which women 65 years and older who have a positive family history of dementia are given premarin/prempro (based on uterine status) versus placebo in an effort to prevent the occurence of Alzheimer's disease in a population that is vulnerable by family history. Our current enrollment in the trial is 28 women, and we are still actively enrolling. This trial is supported by an RO-1 to Dr. Mary Sano, who recently moved from Columbia to Mt. Sinai in New York. During the competitive renewal site visit, the RO-1 received a score of 159, and is confident that the funding will continue for another five years to support this ongoing work.